Potent

Minghui Pharmaceutical to Present the Phase I/II Study of MHB088C (B7-H3 ADC) for the Treatment of Patients with Recurrent or Metastatic Solid Tumors in Late-breaking Oral Presentation at the 2024 ASCO Annual Meeting

Retrieved on: 
星期三, 五月 8, 2024
Phase, ADC, Potent

SHANGHAI, May 8, 2024 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a late-stage clinical biopharmaceutical company focused on autoimmune diseases and oncology, will feature Dr. Lin Shen from Beijing Cancer Hospital at the upcoming ASCO Annual Meeting in Chicago.

Key Points: 
  • SHANGHAI, May 8, 2024 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a late-stage clinical biopharmaceutical company focused on autoimmune diseases and oncology, will feature Dr. Lin Shen from Beijing Cancer Hospital at the upcoming ASCO Annual Meeting in Chicago.
  • Dr. Shen will present the results from the Phase I/II clinical study of MHB088C, a well-differentiated B7-H3-targeting antibody-drug conjugate (ADC) for recurrent or metastatic solid tumors, in an oral presentation.
  • Abstract Title: Results of a Phase 1/2 Study of MHB088C: a Novel B7-H3 Antibody-Drug Conjugate (ADC) Incorporating a Potent DNA Topoisomerase I Inhibitor in Recurrent or Metastatic Solid Tumors

Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties

Retrieved on: 
星期三, 四月 10, 2024
Cardiotoxicity, RTCA, Mouse, STS, Doxorubicin, Heart, Animal, Molecule, Pathology, AML, Potent, Anthracycline, DNA, Patent, Patient, Physiology, Virus, Toxicity, Acute myeloid leukemia, AACR, United States patent law, Pharmaceutical industry

HOUSTON, April 10, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced positive preclinical data regarding the Company's next-generation anthracycline, Annamycin, was presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10, 2024 in San Diego, CA.

Key Points: 
  • The poster titled, Non-cardiotoxic Properties of Annamycin, a Clinically Evaluated Anthracycline and Potent Topoisomerase 2β Poison , was presented in the "Late-Breaking Research: Experimental and Molecular Therapeutics 2" session held on Monday, April 8th.
  • These data, documenting lack of cardiotoxicity of Annamycin and aligned with the data demonstrated to date in our ongoing clinical trials, bolster our confidence in Annamycin potential to offer patients a safe and effective treatment option.
  • Annamycin and doxorubicin cytotoxicity was assessed in a panel of cancer cell lines cardiomyocytes (murine and human).
  • For more information about the ongoing trials, please visit clinicaltrialsregister.eu : EudraCT 2020-005493-10 or clinicaltrials.gov : NCT05319587; and clinicaltrials.gov : NCT04887298, respectively.

Schrödinger Presents Data Supporting Advancement of SGR-1505 and SGR-2921 at American Society of Hematology 2023 Annual Meeting

Retrieved on: 
星期日, 十二月 10, 2023
Oncology, Health, Technology, Health Technology, Software, Pharmaceutical, Biotechnology, Webcast, Cytokine, Decitabine, Safety, CDC7, Lymphoid leukemia, ASH, Acute myeloid leukemia, Harmonic pitch class profiles, B-cell lymphoma, Patient, Abstract, NF, Pharmacokinetics, Therapy, Venetoclax, Chronic lymphocytic leukemia, Significance, Trial of the century, Human, MALT1, AML, Potent, Cancer, Society, Myelodysplastic syndrome, NHL, CLL, Pharmaceutical industry, Vaccine

The preclinical data reported show that both SGR-1505 and SGR-2921 have multiple favorable attributes and the potential for combination activity with standard-of-care agents.

Key Points: 
  • The preclinical data reported show that both SGR-1505 and SGR-2921 have multiple favorable attributes and the potential for combination activity with standard-of-care agents.
  • The company will report additional data from the healthy subject study at its Pipeline Day on December 14, 2023.
  • “The pharmacological data for SGR-1505 and SGR-2921 demonstrate that our development candidates have favorable, differentiated profiles with best-in-class potential,” stated Karen Akinsanya, Ph.D., president of R&D therapeutics at Schrödinger.
  • “Our progress within these programs further validates our computational approach to designing therapies with the potential to address the limitations of current treatments.

Global Marketing Automation Strategic Analysis Report 2023-2030: Growing Focus on Mobile-First Approach Creates Robust Opportunities, Cloud-Based Marketing Automation to Gain Prominence

Retrieved on: 
星期五, 十二月 1, 2023
Cloud, Social media, Marketing automation, Growth, Marketing, Automation, Potent, Speciality chemicals, Retail

DUBLIN, Nov. 30, 2023 /PRNewswire/ -- The "Marketing Automation - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Nov. 30, 2023 /PRNewswire/ -- The "Marketing Automation - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • Cloud, one of the segments analyzed in the report, is projected to record 10.2% CAGR and reach US$6.2 Billion by the end of the analysis period.
  • In today's digital age, as digital marketing becomes mainstream, marketing automation technologies are gaining increasing importance and becoming indispensable for businesses.
  • Marketing automation encompasses a wide scope and offers numerous benefits, such as improved efficiency, better customer engagement, and data-driven decision-making.

Black Hat Announces Content Lineup for Black Hat Europe 2023

Retrieved on: 
星期四, 十月 19, 2023
Technology, Security, Software, Networks, Internet, Training, IOT (Internet of Things), Education, Artificial Intelligence, Internet of things, Quadream, Psoas, August, Poisoning, Hat, The Nightmare Before Christmas, Potent, LLM, Engineering, London, IOS, Arsenal, Completion, Internet Security Awareness Training, ExCeL London, Certificate of Completion of Training, DNS, Outline

Black Hat , the producer of the cybersecurity industry’s most established and in-depth security events, today announced the release of its content lineup for Black Hat Europe 2023.

Key Points: 
  • Black Hat , the producer of the cybersecurity industry’s most established and in-depth security events, today announced the release of its content lineup for Black Hat Europe 2023.
  • The live, in-person event will take place at ExCeL London from December 4 to December 7, and feature 40 Briefings hand selected by the Black Hat Europe Review Board, four days of Trainings, over 50 Sponsored Sessions, and 50 Arsenal tool demos.
  • On December 6 and December 7, attendees will gain insight into the latest in information security risks, developments, and trends.
  • Briefings highlights include:
    Sweet QuaDreams or Nightmare Before Christmas?

Ryvu Therapeutics to Present Preclinical Data on PRMT5 and its Synthetic Lethality Platform at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
星期三, 十月 4, 2023
MTAP, CRISPR, Intellectual property, AACR, B-cell lymphoma, CRC, Molecular mechanics, WSE, MTA, DLBCL, Neoplasm, RNA-Seq, Mantle cell lymphoma, Large intestine, Cell, Transcriptome, Colorectal cancer, Potent, Lymphoma, PIM, CEST, Apoptosis, Genetic distance, Step Forward, Therapy, Conference, PRMT5, Cryptocurrency, Pharmaceutical industry, Vaccine

“During this year's AACR-NCI-EORTC conference, we will present data from our most advanced preclinical project on MTA-cooperative PRMT5 inhibitors, representing the flagship initiative within Ryvu’s synthetic lethality platform.

Key Points: 
  • “During this year's AACR-NCI-EORTC conference, we will present data from our most advanced preclinical project on MTA-cooperative PRMT5 inhibitors, representing the flagship initiative within Ryvu’s synthetic lethality platform.
  • Details on the poster presentations are as follows:
    Ryvu has developed potentially best-in-class MTA-cooperative PRMT5 inhibitors showing favorable properties and effective PRMT5 inhibition dependent on MTA.
  • Ryvu has developed a comprehensive platform using CRC model cells derived from human intestinal stem cells, patient-derived xenografts, and clinical samples.
  • Ryvu will host a webinar on Monday, October 16, at 9:30 am CEST to discuss the PRMT5 data.

ContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens at ASM Microbe 2023

Retrieved on: 
星期四, 六月 8, 2023
Klebsiella pneumoniae, Campaign, ASM, XDR, Potent, Conference, Yersinia pestis, Peptide, Vaccine, Klebsiella

YONKERS, N.Y., June 08, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces that the Company has been selected to present four posters at the ASM Microbe Conference to be held in Houston, Texas from June 15-19, 2023.

Key Points: 
  • YONKERS, N.Y., June 08, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces that the Company has been selected to present four posters at the ASM Microbe Conference to be held in Houston, Texas from June 15-19, 2023.
  • The data being presented will feature CF-370 demonstrating efficacious activity in a neutropenic rabbit pneumonia model against an extensively-drug-resistant (XDR) strain of Klebsiella pneumoniae (K. pneumoniae).
  • ASM Microbe 2023 Poster Presentation Details:
    Engineered Lysins with Potent In Vitro Activity Against Burkholderia spp.
  • and Yersinia pestis

Sarah Cannon Research Institute to Present Latest Oncology Research Insights at 2023 ASCO® Annual Meeting

Retrieved on: 
星期四, 六月 1, 2023
Science, Health, Oncology, Research, Head, Lead, FACOG, DO, HealthOne, Colorectal cancer, Spacecraft, Sarah Cannon Research Institute, Otorhinolaryngology, Coronation of the British monarch, Atezolizumab, McKesson Corporation, Cancer, Sunitinib, Breast, MS, Adjuvant, Carcinoma, Randomness, Conjugation, Phase, Combination, Abstract, Metastasis, SCRI, HR, Kidney, MPH, Doctor of Pharmacy, Highlight, Lung, ASCO, Potent, American Society of Clinical Oncology, Physician, FRA, Annual general meeting, FACS, Thomas Jefferson National Accelerator Facility, CDT, Society, Sodium-dependent phosphate transport protein 2B, Nursing, Pharmaceutical industry, Music, Medical imaging, Safety, E450, MD, Pharmacokinetics, Pembrolizumab, Master of Medicine, Efficacy, Patient

Sarah Cannon Research Institute (SCRI) announced that its network of research leaders have been selected to deliver insights through more than 135 abstracts and presentations at the 2023 American Society of Clinical Oncology (ASCO®) Annual Meeting June 2-6, 2023.

Key Points: 
  • Sarah Cannon Research Institute (SCRI) announced that its network of research leaders have been selected to deliver insights through more than 135 abstracts and presentations at the 2023 American Society of Clinical Oncology (ASCO®) Annual Meeting June 2-6, 2023.
  • In 2022, SCRI joined together with US Oncology Research as one company to transform oncology research and improve care in more than 24 states across the U.S. Operating as SCRI, the unified research network has over 1,300 physicians enrolling patients to more than 1,000 trials annually.
  • “The collaborations across SCRI’s expanded network are accelerating progress and serving more patients closer to where they live,” says Howard A.
  • “We are looking forward to this year’s Annual Meeting where we will be discussing the results of trials that are advancing therapies across a variety of cancers.”
    For a comprehensive list of abstracts and presentations, click here .

Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023

Retrieved on: 
星期二, 三月 14, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Molecule, Phosphatidylinositol, AACR, Lenalidomide, Lung cancer, APC Activator, Abstract, DLBCL, Clinical trial, Refractory, Anemia, Relapse, Potent, Tumor microenvironment, Phosphatase, BTK, BET inhibitor, Drug resistance, Bone marrow, MPN, Myeloproliferative neoplasm, ALK2, American Association for Cancer Research, Efficacy, Treatment, Fibroblast growth factor receptor, FGFR, Pharmaceutical industry, Vaccine, Patient, Macrophage, Incyte, Primary myelofibrosis, Pemigatinib

Incyte (Nasdaq:INCY) today announced that multiple abstracts from across its oncology portfolio will be presented during the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, held April 14-19, in Orlando, Florida.

Key Points: 
  • Incyte (Nasdaq:INCY) today announced that multiple abstracts from across its oncology portfolio will be presented during the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, held April 14-19, in Orlando, Florida.
  • ET)
    Five-Year Safety and Efficacy of Tafasitamab in Patients with Relapsed or Refractory DLBCL: Final Results from the Phase 2 L-MIND Study1(Abstract #CT022.
  • ET)
    For registered attendees, the virtual meeting platform and all on-demand sessions will be available through July 19, 2023.
  • More information regarding the AACR Annual Meeting 2023 can be found at https://www.aacr.org/meeting/aacr-annual-meeting-2023/ .

Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research

Retrieved on: 
星期三, 三月 8, 2023
Health, Infectious Diseases, COVID-19, Clinical Trials, Research, Science, Biotechnology, Treatment, ICAR, Mitigation, Viral, CET, International Conference on Emerging Infectious Diseases, SARS-CoV-2, Potent, Antiviral Research, Conference, Potential, Tissue, Medication, Pharmaceutical industry, Vaccine, Powder metallurgy

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that data for EDP-235, its lead 3CL protease inhibitor in development as an oral, once-daily treatment for COVID-19, will be presented at the 36th International Conference on Antiviral Research (ICAR) being held March 13-17, 2023 at the Centre De Congres De Lyon (Lyon Convention Center) in Lyon, France.

Key Points: 
  • Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that data for EDP-235, its lead 3CL protease inhibitor in development as an oral, once-daily treatment for COVID-19, will be presented at the 36th International Conference on Antiviral Research (ICAR) being held March 13-17, 2023 at the Centre De Congres De Lyon (Lyon Convention Center) in Lyon, France.
  • New clinical data being highlighted include results from a Phase 1 study of EDP-235.
  • Additionally, new preclinical findings regarding EDP-235’s effect on replication and transmission, as well as its potential to mitigate viral rebound, will be presented.
  • Further information about ICAR 2023 can be found here .